公司資料
Neurogene 股價、新聞與催化劑
- 股票代碼:
- NGNE
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
26.55 USD (-4.57%)
收盤價
最後更新: 2026年10月1日
413M USD
市值
股價為何變動
截至 2026年10月1日，NGNE 下跌 4.57%，收於 $26.55。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
業務概覽
Neurogene is a gene-therapy company focused on rare neurological diseases. Its story is centered on bringing genetic medicine to severe CNS disorders with very high unmet need.
所在地與產業分類
Neurogene is headquartered in the United States and listed on NASDAQ. It sits in gene therapy and neuroscience biotechnology.
商業模式特徵
The company depends on clinical progress, manufacturing execution, and the ability to fund a narrow rare-disease pipeline. Investors watch early data and safety closely.
生技產業定位
Neurogene occupies a premium but high-risk gene-therapy niche within biotech. The stock is catalyst-sensitive because the company’s value is tightly linked to a small set of gene-therapy assets.
未來催化劑
- Neurogene’s catalysts are NGN-401 and the Rett-syndrome / neurogenetic platform, with each update potentially moving the stock quickly. The company remains early and highly data-dependent.
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。